116 related articles for article (PubMed ID: 3017398)
1. Enhanced transplantability of human ovarian cancer lines in cyclophosphamide-pretreated nude mice.
Nauta MM; Boven E; Schlüper HM; Erkelens CA; Pinedo HM
Br J Cancer; 1986 Aug; 54(2):331-5. PubMed ID: 3017398
[No Abstract] [Full Text] [Related]
2. Characterization of human ovarian cancer lines with a panel of monoclonal antibodies (MoAbs).
Molthoff CF; Boven E; Calame JJ; van Beek PJ; Pinedo HM
Strahlenther Onkol; 1989 Jul; 165(7):494-5. PubMed ID: 2546266
[No Abstract] [Full Text] [Related]
3. Cellular immunologic responsiveness to extracts of ovarian epithelial tumors.
Melnick H; Barber HR
Gynecol Oncol; 1975 Mar; 3(1):77-86. PubMed ID: 168133
[No Abstract] [Full Text] [Related]
4. An immunohistochemical study of distribution of carcinoembryonic antigen in epithelial tumours of the ovary.
Heald J; Buckley CH; Fox H
J Clin Pathol; 1979 Sep; 32(9):918-26. PubMed ID: 229130
[TBL] [Abstract][Full Text] [Related]
5. Enhanced success rate of transplantation with human tumors in cyclophosphamide-treated nude mice.
Braakhuis BJ; Nauta MM; Romijn JC; Rutgers DH; Smink T
J Natl Cancer Inst; 1986 Feb; 76(2):241-5. PubMed ID: 3456063
[TBL] [Abstract][Full Text] [Related]
6. Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary.
Maughan TS; Fish RG; Shelley M; Jasani B; Williams GT; Adams M
Gynecol Oncol; 1988 Jul; 30(3):342-6. PubMed ID: 2839394
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of pre-operative serum CA 125 in ovarian cancer.
Cruickshank DJ; Fullerton WT; Klopper A
Br J Obstet Gynaecol; 1987 Jul; 94(7):692-5. PubMed ID: 2441738
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell activity and progression-free survival in ovarian cancer.
Garzetti GG; Cignitti M; Ciavattini A; Fabris N; Romanini C
Gynecol Obstet Invest; 1993; 35(2):118-20. PubMed ID: 8383627
[TBL] [Abstract][Full Text] [Related]
9. Carcinoembryonic antigen isotypes in tissue sections and loose cyst fluid cells of ovarian neoplasms.
Harłozińska A; Bar JK; Jothy S; Sedlaczek P; Slesak B; Richter R
Tumour Biol; 1993; 14(1):1-8. PubMed ID: 7684152
[TBL] [Abstract][Full Text] [Related]
10. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
11. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of immunoglobulins in the effusions of human ovarian epithelial neoplasms.
Kutteh WH; Gall SA; Doellgast GJ; Allitto BA; Dawson JR
Am J Obstet Gynecol; 1984 Sep; 150(1):65-9. PubMed ID: 6476028
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
15. Restorative effects of defective autologous lymphocyte cytotoxicity by calmodulin antagonists.
Kikuchi Y; Oomori K; Kizawa I; Kato K
Biochem Biophys Res Commun; 1985 Oct; 132(2):620-7. PubMed ID: 4062941
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of secretory component levels in cyst fluids, ascitic fluids, and sera from ovarian adenocarcinoma patients.
Klein JL; Gall SA; Dawson JR
J Natl Cancer Inst; 1978 Jul; 61(1):57-60. PubMed ID: 209204
[TBL] [Abstract][Full Text] [Related]
17. Immunological reactivity of mucinous and serous ovarian adenocarcinomas.
Harłozińska-Szmyrka A; Slesak B; Richter R; Rabczyński J; Cisło M
Cancer Detect Prev; 1986; 9(3-4):347-58. PubMed ID: 3017557
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of the tumor marker CA125 in ovarian tumor (a cooperative study among 8 institutions)].
Kato T; Nishimura H; Hamai J; Yamabe T; Nakajima H; Nakano T; Noda K; Teshima K; Suzuki H; Ueda G
Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2338-45. PubMed ID: 3007640
[No Abstract] [Full Text] [Related]
19. [Biological properties of two newly established cell lines (RMUG-S, RMUG-L) from a human ovarian mucinous cystadenocarcinoma].
Sakayori M; Nozawa S; Udagawa Y; Chin K; Lee SG; Sakuma T; Iizuka R; Wada Y; Yoshida S; Takeda Y
Hum Cell; 1990 Mar; 3(1):52-6. PubMed ID: 2083224
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor effect of PSK and its combined effect with CDDP on ovarian serous adenocarcinoma-bearing nude mice].
Ishii K; Kita T; Hirata J; Tode T; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Apr; 45(4):333-9. PubMed ID: 8509669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
